admin – Page 5312 – Get News Story

Idiopathic Pulmonary Fibrosis Pipeline Forecast 2024: FDA Approvals, Therapies, and Treatment Outlook | FibroGen, MediciNova, Pliant Therapeutics, Horizon Pharma, Reviva Pharma, Roche, Vicore Pharma

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Idiopathic Pulmonary Fibrosis pipeline constitutes 80+ key companies continuously working towards developing 100+ Idiopathic Pulmonary Fibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Idiopathic Pulmonary Fibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Idiopathic Pulmonary Fibrosis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Idiopathic Pulmonary Fibrosis Market.

Some of the key takeaways from the Idiopathic Pulmonary Fibrosis Pipeline Report:

Companies across the globe are diligently working toward developing novel Idiopathic Pulmonary Fibrosis treatment therapies with a considerable amount of success over the years.
Idiopathic Pulmonary Fibrosis companies working in the treatment market are FibroGen, MediciNova, Pliant Therapeutics, Horizon Pharmaceuticals, Reviva Pharmaceuticals, Roche, Vicore Pharma, Aria Pharmaceuticals, InSilico Medicine, AdAlta, AstraZeneca, Lung Therapeutics, CSL Behring, Galecto Biotech AB, Pliant Therapeutics, Endeavor BioMedicine, FibroGen, Boehringer Ingelheim, and others, are developing therapies for the Idiopathic Pulmonary Fibrosis treatment

Emerging Idiopathic Pulmonary Fibrosis therapies in the different phases of clinical trials are- Pamrevlumab, Tipelukast, PLN-74809, HZN-825, Brilaroxazine, PRM-151, C21, TXR 1002, INS018_055, AD-214, AZD5055, LTI-03, CSL312, GB0139, PLN-74809, ENV-101, Pamrevlumab, BI-1015550, and others are expected to have a significant impact on the Idiopathic Pulmonary Fibrosis market in the coming years.
In September 2024, Insilico Medicine has reported encouraging preliminary results from its Phase IIa clinical trial of ISM001-055, a small molecule drug developed using generative AI for the treatment of idiopathic pulmonary fibrosis (IPF). The randomized, double-blind, placebo-controlled trial was conducted at 21 sites in China, enrolling 71 patients with IPF. It evaluated the safety, tolerability, pharmacokinetics, and preliminary efficacy of 12 weeks of oral ISM001-055. The study included four groups: a placebo group, and three treatment groups receiving 30 mg once daily (QD), 30 mg twice daily (BID), and 60 mg QD.
In July 2024, South Korean biotechnology company Bridge Biotherapeutics has completed enrollment for its Phase II clinical trial of BBT-877, a novel autotaxin inhibitor developed for the treatment of idiopathic pulmonary fibrosis (IPF).
In May 2024, Aileron Therapeutics has announced positive results from the first cohort of its ongoing Phase Ib clinical trial evaluating inhaled LTI-03 in patients with idiopathic pulmonary fibrosis (IPF). This randomized, double-blind, placebo-controlled, multicenter dose-escalation study includes recently diagnosed IPF patients who have not received anti-fibrotic treatment for at least two months.
In December 2023, Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company, has announced the initiation of its Phase 2b CORAL clinical trial, which will evaluate three doses of Haduvio™ (oral nalbuphine ER) in comparison to a placebo in around 160 idiopathic pulmonary fibrosis (IPF) patients with chronic cough. This Phase 2b trial builds on the success of the Phase 2a CANAL trial, which showed a 75.1% reduction in daytime cough frequency, representing a 52.5% improvement over placebo (p<0.0001). Haduvio is also being developed for refractory chronic cough (RCC) and prurigo nodularis.

Idiopathic Pulmonary Fibrosis Overview

Idiopathic Pulmonary Fibrosis (IPF) is a chronic and progressive lung disease characterized by the scarring (fibrosis) of the lung tissue. In IPF, the lung tissue becomes thickened, stiff, and scarred over time, making it difficult for the lungs to function properly and limiting the ability to breathe.

Get a Free Sample PDF Report to know more about Idiopathic Pulmonary Fibrosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-pipeline-insight

Emerging Idiopathic Pulmonary Fibrosis Drugs Under Different Phases of Clinical Development Include:

Pamrevlumab: FibroGen
Tipelukast: MediciNova
PLN-74809: Pliant Therapeutics
HZN-825: Horizon Pharmaceuticals
Brilaroxazine: Reviva Pharmaceuticals
PRM-151: Roche
C21: Vicore Pharma
TXR 1002: Aria Pharmaceuticals
INS018_055: InSilico Medicine
AD-214: AdAlta
AZD5055: AstraZeneca
LTI-03: Lung Therapeutics
CSL312: CSL Behring
GB0139: Galecto Biotech AB
PLN-74809: Pliant Therapeutics
ENV-101: Endeavor BioMedicine
Pamrevlumab: FibroGen
BI-1015550: Boehringer Ingelheim

Idiopathic Pulmonary Fibrosis Route of Administration

Idiopathic Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Idiopathic Pulmonary Fibrosis Molecule Type

Idiopathic Pulmonary Fibrosis Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Idiopathic Pulmonary Fibrosis Pipeline Therapeutics Assessment

Idiopathic Pulmonary Fibrosis Assessment by Product Type
Idiopathic Pulmonary Fibrosis By Stage and Product Type
Idiopathic Pulmonary Fibrosis Assessment by Route of Administration
Idiopathic Pulmonary Fibrosis By Stage and Route of Administration
Idiopathic Pulmonary Fibrosis Assessment by Molecule Type
Idiopathic Pulmonary Fibrosis by Stage and Molecule Type

DelveInsight’s Idiopathic Pulmonary Fibrosis Report covers around 100+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Idiopathic Pulmonary Fibrosis product details are provided in the report. Download the Idiopathic Pulmonary Fibrosis pipeline report to learn more about the emerging Idiopathic Pulmonary Fibrosis therapies

Some of the key companies in the Idiopathic Pulmonary Fibrosis Therapeutics Market include:

Key companies developing therapies for Idiopathic Pulmonary Fibrosis are – Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche Ltd, FibroGen Inc., MediciNova Inc., Jubliant Pharma Limited (Jubliant Cadista Limited), Merck & Co. Inc., United Therapeutics, Boehringer Ingelheim International GmbH, Horizon Therapeutics Inc., Avalyn Pharma Inc., CS Pharmaceuticals, and others.

Idiopathic Pulmonary Fibrosis Pipeline Analysis:

The Idiopathic Pulmonary Fibrosis pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Idiopathic Pulmonary Fibrosis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Idiopathic Pulmonary Fibrosis Treatment.
Idiopathic Pulmonary Fibrosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Idiopathic Pulmonary Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Idiopathic Pulmonary Fibrosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Idiopathic Pulmonary Fibrosis drugs and therapies

Idiopathic Pulmonary Fibrosis Pipeline Market Drivers

Changing lifestyle patterns and increasing consumption of nicotine products, diverse and extensive pipeline therapies, rise in the number of geriatric population are some of the important factors that are fueling the Idiopathic Pulmonary Fibrosis Market.

Idiopathic Pulmonary Fibrosis Pipeline Market Barriers

However, Lack of effective treatment options for severe Idiopathic Pulmonary Fibrosis (IPF) cases, exact Cause of IPF is not fully understood, misdiagnosis of Idiopathic Pulmonary Fibrosis (IPF) and other factors are creating obstacles in the Idiopathic Pulmonary Fibrosis Market growth.

Scope of Idiopathic Pulmonary Fibrosis Pipeline Drug Insight

Coverage: Global
Key Idiopathic Pulmonary Fibrosis Companies: FibroGen, MediciNova, Pliant Therapeutics, Horizon Pharmaceuticals, Reviva Pharmaceuticals, Roche, Vicore Pharma, Aria Pharmaceuticals, InSilico Medicine, AdAlta, AstraZeneca, Lung Therapeutics, CSL Behring, Galecto Biotech AB, Pliant Therapeutics, Endeavor BioMedicine, FibroGen, Boehringer Ingelheim, and others
Key Idiopathic Pulmonary Fibrosis Therapies: Pamrevlumab, Tipelukast, PLN-74809, HZN-825, Brilaroxazine, PRM-151, C21, TXR 1002, INS018_055, AD-214, AZD5055, LTI-03, CSL312, GB0139, PLN-74809, ENV-101, Pamrevlumab, BI-1015550, and others
Idiopathic Pulmonary Fibrosis Therapeutic Assessment: Idiopathic Pulmonary Fibrosis current marketed and Idiopathic Pulmonary Fibrosis emerging therapies
Idiopathic Pulmonary Fibrosis Market Dynamics: Idiopathic Pulmonary Fibrosis market drivers and Idiopathic Pulmonary Fibrosis market barriers

Request for Sample PDF Report for Idiopathic Pulmonary Fibrosis Pipeline Assessment and clinical trials

Table of Contents

1. Idiopathic Pulmonary Fibrosis Report Introduction

2. Idiopathic Pulmonary Fibrosis Executive Summary

3. Idiopathic Pulmonary Fibrosis Overview

4. Idiopathic Pulmonary Fibrosis- Analytical Perspective In-depth Commercial Assessment

5. Idiopathic Pulmonary Fibrosis Pipeline Therapeutics

6. Idiopathic Pulmonary Fibrosis Late Stage Products (Phase II/III)

7. Idiopathic Pulmonary Fibrosis Mid Stage Products (Phase II)

8. Idiopathic Pulmonary Fibrosis Early Stage Products (Phase I)

9. Idiopathic Pulmonary Fibrosis Preclinical Stage Products

10. Idiopathic Pulmonary Fibrosis Therapeutics Assessment

11. Idiopathic Pulmonary Fibrosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Idiopathic Pulmonary Fibrosis Key Companies

14. Idiopathic Pulmonary Fibrosis Key Products

15. Idiopathic Pulmonary Fibrosis Unmet Needs

16 . Idiopathic Pulmonary Fibrosis Market Drivers and Barriers

17. Idiopathic Pulmonary Fibrosis Future Perspectives and Conclusion

18. Idiopathic Pulmonary Fibrosis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Idiopathic Pulmonary Fibrosis Pipeline Forecast 2024: FDA Approvals, Therapies, and Treatment Outlook | FibroGen, MediciNova, Pliant Therapeutics, Horizon Pharma, Reviva Pharma, Roche, Vicore Pharma

Irritable Bowel Syndrome Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, MOA, ROA by DelveInsight | P4 Microbiome, Biomica, Invea Therapeutics, RaQualia Pharma, RedHill Biopharma

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Irritable Bowel Syndrome pipeline constitutes 24+ key companies continuously working towards developing 24+ Irritable Bowel Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Irritable Bowel Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Irritable Bowel Syndrome Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Irritable Bowel Syndrome Market.

Some of the key takeaways from the Irritable Bowel Syndrome Pipeline Report:

Companies across the globe are diligently working toward developing novel Irritable Bowel Syndrome treatment therapies with a considerable amount of success over the years.
Irritable Bowel Syndrome companies working in the treatment market are P4 Microbiome, Biomica, Invea Therapeutics, Inc., RaQualia Pharma, RedHill Biopharma Ltd., 4D pharma, SV-MMX Cosmo Pharmaceuticals, and others, are developing therapies for the Irritable Bowel Syndrome treatment

Emerging Irritable Bowel Syndrome therapies such as – P4M01, BMC426, INVA 8002, RQ-00310941, RHB-102, Blautix, Rifamycin, and others are expected to have a significant impact on the Irritable Bowel Syndrome market in the coming years.
In February 2024, CinPhloro Pharma, a portfolio company of CinRx, has announced the dosing of the first participant in its Phase 2 enviva study evaluating CIN-103 for the chronic treatment of irritable bowel syndrome with predominant diarrhea (IBS-D). CIN-103 is a novel formulation of phloroglucinol, designed for long-term use, and is a non-opioid small molecule aimed at addressing multiple aspects of IBS-D, including motility, secretion, pain, spasms, and inflammation.

Irritable Bowel Syndrome Overview

Irritable Bowel Syndrome is a chronic, often debilitating, functional gastrointestinal (GI) disorder. It can begin in childhood, adolescence, or adulthood and can resolve unexpectedly for periods throughout an individual’s lifespan, recurring at any age. The condition causes recurrent attacks of abdominal pain or discomfort in association with bowel habits. The most important single risk factors are female sex, younger age and preceding gastrointestinal infections.

Get a Free Sample PDF Report to know more about Irritable Bowel Syndrome Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-pipeline-insight

Emerging Irritable Bowel Syndrome Drugs Under Different Phases of Clinical Development Include:

P4M01: P4Microbiome
BMC426: Biomica
ORP-101: OrphoMed
INVA 8002: Invea Therapeutics, Inc.
RQ-00310941: RaQualia Pharma
RHB-102: RedHill Biopharma Ltd.
Blautix: 4D pharma
Rifamycin: SV-MMX Cosmo Pharmaceuticals

Route of Administration

Irritable Bowel Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Molecule Type

Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Irritable Bowel Syndrome Pipeline Therapeutics Assessment

Irritable Bowel Syndrome Assessment by Product Type
Irritable Bowel Syndrome By Stage and Product Type
Irritable Bowel Syndrome Assessment by Route of Administration
Irritable Bowel Syndrome By Stage and Route of Administration
Irritable Bowel Syndrome Assessment by Molecule Type
Irritable Bowel Syndrome by Stage and Molecule Type

DelveInsight’s Irritable Bowel Syndrome Report covers around 24+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Irritable Bowel Syndrome product details are provided in the report. Download the Irritable Bowel Syndrome pipeline report to learn more about the emerging Irritable Bowel Syndrome therapies

Some of the key companies in the Irritable Bowel Syndrome Therapeutics Market include:

Key companies developing therapies for Irritable Bowel Syndrome are – Allergan, Ironwood Pharmaceuticals, Inc., Synergy Pharmaceuticals Inc., Bausch Health, Takeda Pharmaceutical Company Limited, AstraZeneca, Sebela Pharmaceuticals Inc., Synthetic Biologics, Inc., Astellas Pharma, Inc., and Ardelyx, and others.

Irritable Bowel Syndrome Pipeline Analysis:

The Irritable Bowel Syndrome pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Irritable Bowel Syndrome with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Irritable Bowel Syndrome Treatment.
Irritable Bowel Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Irritable Bowel Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Irritable Bowel Syndrome market.

Download Sample PDF Report to know more about Irritable Bowel Syndrome drugs and therapies

Irritable Bowel Syndrome Pipeline Market Drivers

Increase in prevalence of gastrointestinal diseases and disorders such as alteration of bowel habit, surge in the level of Unhealthy lifestyle are some of the important factors that are fueling the Irritable Bowel Syndrome Market.

Irritable Bowel Syndrome Pipeline Market Barriers

However, complex diagnostic processes, lack of awareness and other factors are creating obstacles in the Irritable Bowel Syndrome Market growth.

Scope of Irritable Bowel Syndrome Pipeline Drug Insight

Coverage: Global
Key Irritable Bowel Syndrome Companies: P4Microbiome, Biomica, Invea Therapeutics, Inc., RaQualia Pharma, RedHill Biopharma Ltd., 4D pharma, SV-MMX Cosmo Pharmaceuticals, and others
Key Irritable Bowel Syndrome Therapies: P4M01, BMC426, INVA 8002, RQ-00310941, RHB-102, Blautix, Rifamycin, and others
Irritable Bowel Syndrome Therapeutic Assessment: Irritable Bowel Syndrome current marketed and Irritable Bowel Syndrome emerging therapies
Irritable Bowel Syndrome Market Dynamics: Irritable Bowel Syndrome market drivers and Irritable Bowel Syndrome market barriers

Request for Sample PDF Report for Irritable Bowel Syndrome Pipeline Assessment and clinical trials

Table of Contents

1	Irritable Bowel Syndrome Report Introduction
2	Irritable Bowel Syndrome Executive Summary
3	Irritable Bowel Syndrome Overview
4	Irritable Bowel Syndrome- Analytical Perspective In-depth Commercial Assessment
5	Irritable Bowel Syndrome Pipeline Therapeutics
6	Irritable Bowel Syndrome Late Stage Products (Phase II/III)
7	Irritable Bowel Syndrome Mid Stage Products (Phase II)
8	Irritable Bowel Syndrome Early Stage Products (Phase I)
9	Irritable Bowel Syndrome Preclinical Stage Products
10	Irritable Bowel Syndrome Therapeutics Assessment
11	Irritable Bowel Syndrome Inactive Products
12	Company-University Collaborations (Licensing/Partnering) Analysis
13	Irritable Bowel Syndrome Key Companies
14	Irritable Bowel Syndrome Key Products
15	Irritable Bowel Syndrome Unmet Needs
16	Irritable Bowel Syndrome Market Drivers and Barriers
17	Irritable Bowel Syndrome Future Perspectives and Conclusion
18	Irritable Bowel Syndrome Analyst Views
19	Appendix
20	About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Irritable Bowel Syndrome Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, MOA, ROA by DelveInsight | P4 Microbiome, Biomica, Invea Therapeutics, RaQualia Pharma, RedHill Biopharma

Glioblastoma Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, MOA, ROA by DelveInsight | InovioPharma, Pfizer, Roche, ACADIA Pharma, BioNTech, Oncotelic Therapeutics, Autotelic

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Glioblastoma pipeline constitutes 180+ key companies continuously working towards developing 200+ Glioblastoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Glioblastoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Glioblastoma Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Glioblastoma Market.

Some of the key takeaways from the Glioblastoma Pipeline Report:

Companies across the globe are diligently working toward developing novel Glioblastoma treatment therapies with a considerable amount of success over the years.
Glioblastoma companies working in the treatment market are Denovo BioPharma, Apogenix, Cantex, VAXIMM, Mustang Bio, J INTS BIO, Curtana Pharmaceuticals, Prelude Therapeutics, OX2 Therapeutics, Polaris Group, Crimson Biopharm, CNS Pharmaceuticals, MimiVax, Berg, LLC, Ascletis, Denovo Biopharma, Celgene Corporation, and others, are developing therapies for the Glioblastoma treatment

Emerging Glioblastoma therapies in the different phases of clinical trials are – Enzastaurin, Asunercept, Azeliragon, VXM01, MB-101, JIN 001, CT 179, PRT3645, CD200AR L, ADI-PEG 20, CM93, Berubicin, SurVaxM, BPM31510, ASC40, Enzastaurin, Marizomib, and others are expected to have a significant impact on the Glioblastoma market in the coming years.
In July 2024, Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, has announced results from the GBM-AGILE phase II/III study, which assessed paxalisib in comparison to the standard of care (SOC) for patients with glioblastoma, a severe form of brain cancer with a critical need for new treatments. The trial, registered under NCT03522298, aimed to address the urgent therapeutic gap for this life-threatening condition.
In July 2024, The Ivy Brain Tumor Center at Barrow Neurological Institute in the US has initiated dosing for the first participant in the Phase III Gliofocus clinical trial, which is evaluating niraparib, a selective PARP1/2 inhibitor, in adults with newly diagnosed MGMT-unmethylated glioblastoma. This open-label, randomized trial will compare the efficacy of niraparib against temozolomide, the current standard-of-care first-line chemotherapy. Supported by GSK, the trial will include 450 participants across more than 100 clinical sites in 11 countries.
In May 2024, Moleculin Biotech has announced the launch of an investigator-initiated Phase II NU 21C06 clinical trial, supported by funding from the National Institutes of Health (NIH), to evaluate WP1066 in combination with radiation therapy for adults with glioblastoma.
In February 2024, The Institute of Cancer Research (ICR) in London has reported encouraging results from a Phase I/II clinical trial of 2-OHOA, a new drug derived from oleic acid, for the treatment of glioblastoma. Oleic acid, found naturally in animal and vegetable fats like olive oil, is the basis for 2-OHOA, a synthetic lipid designed to inhibit cancer cell growth by restructuring their abnormal membranes.

Glioblastoma Overview

Glioblastoma, also known as glioblastoma multiforme (GBM), is a type of malignant brain tumor that arises from astrocytes, a type of supportive cells in the brain. It is the most aggressive and common form of primary brain cancer in adults. Glioblastomas are highly infiltrative tumors, meaning they spread rapidly and invade surrounding brain tissue, making complete surgical removal difficult.

Get a Free Sample PDF Report to know more about Glioblastoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/glioblastoma-pipeline-insight

Emerging Glioblastoma Drugs Under Different Phases of Clinical Development Include:

Enzastaurin: Denovo BioPharma
Asunercept: Apogenix
Azeliragon: Cantex
VXM01: VAXIMM
MB-101: Mustang Bio
JIN 001: J INTS BIO
CT 179: Curtana Pharmaceuticals
PRT3645: Prelude Therapeutics
CD200AR L: OX2 Therapeutics
ADI-PEG 20: Polaris Group
CM93: Crimson Biopharm
Berubicin: CNS Pharmaceuticals
SurVaxM: MimiVax
BPM31510: Berg, LLC
ASC40: Ascletis
Enzastaurin: Denovo Biopharma
Marizomib: Celgene Corporation

Glioblastoma Route of Administration

Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Glioblastoma Molecule Type

Glioblastoma Products have been categorized under various Molecule types, such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Glioblastoma Pipeline Therapeutics Assessment

Glioblastoma Assessment by Product Type
Glioblastoma By Stage and Product Type
Glioblastoma Assessment by Route of Administration
Glioblastoma By Stage and Route of Administration
Glioblastoma Assessment by Molecule Type
Glioblastoma by Stage and Molecule Type

DelveInsight’s Glioblastoma Report covers around 200+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Glioblastoma product details are provided in the report. Download the Glioblastoma pipeline report to learn more about the emerging Glioblastoma therapies

Some of the key companies in the Glioblastoma Therapeutics Market include:

Key companies developing therapies for Glioblastoma are – Array Biopharma, AstraZeneca, Doule bond Pharmaceuticals, Philogen, Immatics N.V, BioNTech, InovioPharma, Noxxon Pharma, Celgene Corporation, Karyo Pharma, Neugate Theranostics, Novartis, Orphelia Pharma, Merck, Acerta Pharma, Genenta Science, CNS Pharmaceutical, Pfizer, Roche, Oncotelic Therapeutics, Autotelic Therapeutics, ACADIA Pharmaceuticals, Mayo Clinic, Cytogel, Xgene Pharmaceutical, Ascletis, 3-V Biosciences, Yumanity Therapeutics, and others.

Glioblastoma Pipeline Analysis:

The Glioblastoma pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Glioblastoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Glioblastoma Treatment.
Glioblastoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Glioblastoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Glioblastoma market.

Download Sample PDF Report to know more about Glioblastoma drugs and therapies

Glioblastoma Pipeline Market Drivers

Rising incidence of Glioblastoma multiforme, improving Healthcare Infrastructure, demand for New and Effective Drugs are some of the important factors that are fueling the Glioblastoma Market.

Glioblastoma Pipeline Market Barriers

However, aggressive nature of GBM and the complexity of targeting the central nervous system, the current standard of care for patients with newly diagnosed glioblastoma has limited effectiveness and a second line has not been established and other factors are creating obstacles in the Glioblastoma Market growth.

Scope of Glioblastoma Pipeline Drug Insight

Coverage: Global
Key Glioblastoma Companies: Denovo BioPharma, Apogenix, Cantex, VAXIMM, Mustang Bio, J INTS BIO, Curtana Pharmaceuticals, Prelude Therapeutics, OX2 Therapeutics, Polaris Group, Crimson Biopharm, CNS Pharmaceuticals, MimiVax, Berg, LLC, Ascletis, Denovo Biopharma, Celgene Corporation, and others
Key Glioblastoma Therapies: Enzastaurin, Asunercept, Azeliragon, VXM01, MB-101, JIN 001, CT 179, PRT3645, CD200AR L, ADI-PEG 20, CM93, Berubicin, SurVaxM, BPM31510, ASC40, Enzastaurin, Marizomib, and others
Glioblastoma Therapeutic Assessment: Glioblastoma current marketed and Glioblastoma emerging therapies
Glioblastoma Market Dynamics: Glioblastoma market drivers and Glioblastoma market barriers

Request for Sample PDF Report for Glioblastoma Pipeline Assessment and clinical trials

Table of Contents

1. Glioblastoma Report Introduction

2. Glioblastoma Executive Summary

3. Glioblastoma Overview

4. Glioblastoma- Analytical Perspective In-depth Commercial Assessment

5. Glioblastoma Pipeline Therapeutics

6. Glioblastoma Late Stage Products (Phase II/III)

7. Glioblastoma Mid Stage Products (Phase II)

8. Glioblastoma Early Stage Products (Phase I)

9. Glioblastoma Preclinical Stage Products

10. Glioblastoma Therapeutics Assessment

11. Glioblastoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Glioblastoma Key Companies

14. Glioblastoma Key Products

15. Glioblastoma Unmet Needs

16 . Glioblastoma Market Drivers and Barriers

17. Glioblastoma Future Perspectives and Conclusion

18. Glioblastoma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Glioblastoma Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, MOA, ROA by DelveInsight | InovioPharma, Pfizer, Roche, ACADIA Pharma, BioNTech, Oncotelic Therapeutics, Autotelic

Pancreatic Cancer Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Incyte, AbbVie, Ability Pharma, AB Science, AstraZeneca, Eleison

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Pancreatic Cancer pipeline constitutes 290+ key companies continuously working towards developing 300+ Pancreatic Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Pancreatic Cancer Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pancreatic Cancer Market.

The Pancreatic Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Pancreatic Cancer Pipeline Report:

Companies across the globe are diligently working toward developing novel Pancreatic Cancer treatment therapies with a considerable amount of success over the years.
Pancreatic Cancer companies working in the treatment market are Immunocore, Carrick Therapeutics, DEKA Biosciences, Keymed Biosciences, CARsgen Therapeutics, AIM ImmunoTech Inc., Redx Pharma Plc, Rain Oncology, FibroGen, Novartis AG, Merck & Co, AstraZeneca, and others, are developing therapies for the Pancreatic Cancer treatment

Emerging Pancreatic Cancer therapies in the different phases of clinical trials are- IMC-R117C, CT7001, DK210, CMG901, AB011, Rintatolimod, RXC004, RAIN-32, Pamrevlumab, NIS793, Pembrolizumab, Lynparza, and others are expected to have a significant impact on the Pancreatic Cancer market in the coming years.
In September 2024, Trishula Therapeutics, a US-based biotechnology company, has announced positive findings from its Phase I clinical trial of TTX-030, an anti-CD39 antibody developed for the treatment of first-line metastatic pancreatic cancer. The trial evaluated TTX-030 in combination with gemcitabine and nab-paclitaxel, both with and without the investigational anti-PD-1 antibody budigalimab, in patients with pancreatic adenocarcinoma. The results revealed an objective response rate (ORR) of 30%, a median progression-free survival of 7.5 months, and a median overall survival of 19.1 months in the efficacy-evaluable group.
In May 2024, Verastem Oncology has announced promising early results from its ongoing Phase I/II trial evaluating the kinase inhibitor avutometinib for pancreatic cancer treatment. The US-based biopharmaceutical company shared these interim safety and efficacy findings ahead of its presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, set for June 1, 2024. The trial, known as RAMP 205, is a single-arm study assessing the combination of avutometinib and defactinib with standard-of-care chemotherapy agents, gemcitabine and nab-paclitaxel, in patients with previously untreated metastatic pancreatic ductal adenocarcinoma.
In March 2024, Catalan biopharmaceutical company AbilityPharma has obtained a €7m ($7.65m) investment to advance its Phase IIb clinical trial of ABTL0812, an autophagy inducer aimed at treating metastatic pancreatic cancer. This funding round saw participation from a European-Canadian life sciences syndicate, including CTI Life Sciences Fund, Inveready, the EIC Fund, Fitalent, and CDTI Innvierte.

Pancreatic Cancer Overview

Pancreatic cancer is a condition where malignant cells develop in the pancreatic tissues. This type of cancer originates within the pancreas, an abdominal organ positioned behind the lower portion of the stomach. The pancreas, resembling a slender pear lying horizontally, measures approximately 6 inches in length and serves as a gland in the body.

Get a Free Sample PDF Report to know more about Pancreatic Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/pancreatic-cancer-pipeline-insight

Emerging Pancreatic Cancer Drugs Under Different Phases of Clinical Development Include:

IMC-R117C: Immunocore
CT7001: Carrick Therapeutics
DK210: DEKA Biosciences
CMG901: Keymed Biosciences
AB011: CARsgen Therapeutics
Rintatolimod: AIM ImmunoTech Inc.
RXC004: Redx Pharma Plc
RAIN-32: Rain Oncology
Pamrevlumab: FibroGen
NIS793: Novartis AG
Pembrolizumab: Merck & Co
Lynparza: AstraZeneca

Pancreatic Cancer Route of Administration

Pancreatic Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Pancreatic Cancer Molecule Type

Pancreatic Cancer Products have been categorized under various Molecule types, such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Pancreatic Cancer Pipeline Therapeutics Assessment

Pancreatic Cancer Assessment by Product Type
Pancreatic Cancer By Stage and Product Type
Pancreatic Cancer Assessment by Route of Administration
Pancreatic Cancer By Stage and Route of Administration
Pancreatic Cancer Assessment by Molecule Type
Pancreatic Cancer by Stage and Molecule Type

DelveInsight’s Pancreatic Cancer Report covers around 300+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Pancreatic Cancer product details are provided in the report. Download the Pancreatic Cancer pipeline report to learn more about the emerging Pancreatic Cancer therapies

Some of the key companies in the Pancreatic Cancer Therapeutics Market include:

Key companies developing therapies for Pancreatic Cancer are – AB Science, AstraZeneca, Eleison Pharmaceuticals, ImmunityBio, SynerGene Therapeutics, Inc., Mirati Therapeutics Inc., FibroGen, SynCore Biotechnology, Jiangsu HengRui Medicine, Biosplice Therapeutics, Incyte Corporation, AbbVie, Ability Pharmaceuticals SL, Legend Biotech USA Inc, Biomea Fusion Inc., Astellas Pharma Inc, Cue Biopharma, PureTech, and others.

Pancreatic Cancer Pipeline Analysis:

The Pancreatic Cancer pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Pancreatic Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pancreatic Cancer Treatment.
Pancreatic Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Pancreatic Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pancreatic Cancer market.

Download Sample PDF Report to know more about Pancreatic Cancer drugs and therapies

Pancreatic Cancer Pipeline Market Drivers

Emergence of genomic profiling technologies and selective molecular targeted therapies, emergence of effective therapeutic options for metastatic pool are some of the important factors that are fueling the Pancreatic Cancer Market.

Pancreatic Cancer Pipeline Market Barriers

However, delayed detection and screening of the disease, stromal barriers to drug delivery within the TME in pancreatic cancer and other factors are creating obstacles in the Pancreatic Cancer Market growth.

Scope of Pancreatic Cancer Pipeline Drug Insight

Coverage: Global
Key Pancreatic Cancer Companies: Immunocore, Carrick Therapeutics, DEKA Biosciences, Keymed Biosciences, CARsgen Therapeutics, AIM ImmunoTech Inc., Redx Pharma Plc, Rain Oncology, FibroGen, Novartis AG, Merck & Co, AstraZeneca, and others
Key Pancreatic Cancer Therapies: IMC-R117C, CT7001, DK210, CMG901, AB011, Rintatolimod, RXC004, RAIN-32, Pamrevlumab, NIS793, Pembrolizumab, Lynparza, and others
Pancreatic Cancer Therapeutic Assessment: Pancreatic Cancer current marketed and Pancreatic Cancer emerging therapies
Pancreatic Cancer Market Dynamics: Pancreatic Cancer market drivers and Pancreatic Cancer market barriers

Request for Sample PDF Report for Pancreatic Cancer Pipeline Assessment and clinical trials

Table of Contents

1. Pancreatic Cancer Report Introduction

2. Pancreatic Cancer Executive Summary

3. Pancreatic Cancer Overview

4. Pancreatic Cancer- Analytical Perspective In-depth Commercial Assessment

5. Pancreatic Cancer Pipeline Therapeutics

6. Pancreatic Cancer Late Stage Products (Phase II/III)

7. Pancreatic Cancer Mid Stage Products (Phase II)

8. Pancreatic Cancer Early Stage Products (Phase I)

9. Pancreatic Cancer Preclinical Stage Products

10. Pancreatic Cancer Therapeutics Assessment

11. Pancreatic Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Pancreatic Cancer Key Companies

14. Pancreatic Cancer Key Products

15. Pancreatic Cancer Unmet Needs

16 . Pancreatic Cancer Market Drivers and Barriers

17. Pancreatic Cancer Future Perspectives and Conclusion

18. Pancreatic Cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pancreatic Cancer Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Incyte, AbbVie, Ability Pharma, AB Science, AstraZeneca, Eleison

Designer launches Kickstarter Campaign for 19th Century Authors’ Playing Cards

Now Seeking Community Support via Kickstarter, This Deck of Playing Cards is Inspired by the Famous 19th Century Novels & Their Authors!

Andrea is an Australian-German architect / designer based in rural France and she has proudly announced to launch an exciting new project comprising of a new deck of 54 playing cards. These cards are based on the authors and their novels of the 19th century. Those cards are introduced to the world by launching a crowdfunding campaign on Kickstarter, and generous community support and backing for the project is welcome!

As an architect with more than 20 years of professional experience, Andrea knows how to work reliably and meet deadlines. She has a reputation for working with the best suppliers, with high quality prints and materials. Backers supporting this Kickstarter campaign have the option of ordering these casino quality cards deck in a beautiful black box with a gold foil emblem and a magnetic closure.

“For this project, I have chosen four European authors and brought their characters to life,” said Andrea, the creator of The 19th Century Authors‘ Playing Cards, while introducing this project to the Kickstarter community. “The deck includes legendary authors such as Bram Stoker, Jules Verne, Sir Arthur Conan Doyle, Lewis Carroll and Oscar Wilde. The backs of the cards have a beautiful motif by William Morris.”

The Kickstarter Campaign is located on the web at:

www.kickstarter.com/projects/19thauthors/the-19th-century-authors-playing-cards and backers from around the world can become a part of this project by making generous pledges and donations. Moreover, the goal of this Kickstarter campaign is to raise a sum of EUR 5,500 and the artist is offering these high quality playing cards as a reward with worldwide shipping. Furthermore, more details are available on the Kickstarter campaign page of the project.

About This Project

The 19th Century Authors’ Playing Cards is an exciting new project of a casino quality playing cards deck depicting the iconic 19th century novels and their authors. From Oscar Wilde to Sir Arthur Conan Doyle, these cards celebrate some of the most iconic authors of all time. Created by the designer and architect Andrea, this project is currently being crowdfunded on Kickstarter, and backers from around the world can pledge to support this campaign.

Media Contact
Company Name: The 19th century authors’ Playing Cards
Contact Person: Andrea Neu
Email: Send Email
City: Mareuil
State: Dordogne
Country: France
Website: www.kickstarter.com/projects/19thauthors/the-19th-century-authors-playing-cards

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Designer launches Kickstarter Campaign for 19th Century Authors’ Playing Cards

ZenaTech’s (Nasdaq: ZENA) Nasdaq Listing: A Launchpad for Growth and Innovation

On October 1, ZenaTech (Nasdaq: ZENA) made its debut on the Nasdaq, a pivotal milestone for the company specializing in AI-driven drone solutions and enterprise SaaS (software-as-a-service) applications. As businesses increasingly seek innovative ways to streamline operations and boost productivity, ZenaTech stands ready to meet these demands with its advanced AI drone solutions and comprehensive software applications. Under the leadership of CEO Dr. Shaun Passley, ZenaTech aims to leverage its innovative capabilities to address mission-critical business needs across sectors like law enforcement, agriculture, defense, and logistics. With over 100 enterprise software clients currently using its solutions, ZenaTech is poised to expand its investor base and accelerate future growth.

“We are pleased ZenaTech has reached the status of a publicly listed company on Nasdaq,” said CEO Dr. Shaun Passley. “This achievement will help expand our universe of potential investors and will enable our growth plans for drone solutions, incorporating software and hardware innovations for inspection, monitoring, compliance, field service, and other applications to meet current customer demand.”

ZenaDrone 1000: Advanced Drone Technology for Diverse Industries

At the forefront of ZenaTech’s innovations is the ZenaDrone 1000, an advanced unmanned aerial vehicle (UAV) designed to meet the needs of industries ranging from agriculture to defense. This UAV combines cutting-edge machine learning software with custom hardware to deliver high precision, efficiency, and versatility. Its octocopter configuration allows for superior lift, stability, and maneuverability, while its long-lasting battery and automatic charging capabilities ensure extended flight time for continuous operations.

The ZenaDrone 1000 excels in applications such as aerial surveillance, inspection, and monitoring. With a 4K stabilized camera, smart multispectral sensors, and intelligent flight modes, it’s designed for precision in data capture and analysis. Whether monitoring crops for insurance assessments or scanning power lines for maintenance, the ZenaDrone 1000 provides a reliable, cost-effective solution for companies seeking to optimize their operations.

ZenaTech further enhances its drone offerings with a flexible Drone as a Service (DaaS) model. This service allows businesses to purchase, rent, or subscribe to the ZenaDrone 1000 for scanning and surveillance purposes. Clients can share the costs of drone services with nearby entities, making advanced drone technology more accessible. ZenaTech provides expert support, including trained pilots and engineers, to ensure smooth deployment and operation of the drones.

With its focus on customization, ZenaTech tailors the ZenaDrone 1000’s features—such as VTOL flight modes, carbon fiber construction, and automatic charging systems—to the specific needs of industries like construction, environmental monitoring, military surveillance, and agriculture. The drone’s robust design and range of features make it a key tool in improving operational efficiency, safety, and data collection across sectors.

A Suite of Innovative Solutions

ZenaTech’s offerings are designed to enhance operational efficiency and reduce costs for clients across various industries. Here are some of the standout products reflecting ZenaTech’s commitment to innovation and customer satisfaction:

WorkAware: Streamlining Safety Management

WorkAware is a comprehensive safety management platform tailored for organizations across multiple sectors. Its user-friendly interface simplifies compliance management and enhances operational workflows. Key features like journey management and location tracking empower organizations to effectively supervise remote workers,, while asset management capabilities streamline maintenance schedules. By digitizing workflows, WorkAware increases profitability and mitigates liability for businesses in high-risk environments.

PsPortals: Empowering Public Safety

PsPortals offers essential tools for law enforcement and criminal justice professionals, designed with input from industry experts. Its compliance with NCIC and Nlets standards ensures rapid information exchange, vital for agencies relying on real-time data access. The platform’s features, including the Portal XL, provide a zero-footprint solution that simplifies operations while enhancing security.

SystemView: Automated Facility Management

Initially focusing on utility industries, SystemView excels in automated facility management. Its SCADA (Supervisory Control and Data Acquisition) software provides real-time monitoring and control for various applications, ensuring operational efficiency and minimizing errors. Utilizing advanced HMI (Human-Machine Interface) software, SystemView enables remote management of complex machinery, showcasing ZenaTech’s commitment to optimizing operations across diverse sectors.

TillerStack: Optimizing Field Service Management

TillerStack addresses the complexities of managing field service teams. With tools for dispatching, route optimization, and performance monitoring, this software empowers businesses to enhance service quality while reducing operational costs. TillerStack improves communication and real-time monitoring, significantly boosting customer satisfaction and operational efficiency.

Pace+: Revolutionizing Healthcare Management

In the healthcare sector, ZenaTech’s Pace+ platform offers a cloud-based electronic health record (EHR) and practice management solution. Designed for behavioral and mental health facilities, Pace+ streamlines documentation, scheduling, and reporting processes, transforming the healthcare experience with its modern, flexible platform.

ZigVoice: Enhancing Contact Center Efficiency

ZigVoice specializes in providing innovative solutions for contact centers, enabling businesses to achieve maximum efficiency. Its MCCS (Multi-Channel Contact Solution) platform integrates various telecommunication systems to provide unified reporting and analytics, equipping organizations to enhance customer service and streamline operations.

The rising demand for AI-driven solutions in sectors like agriculture, logistics, and public safety presents a significant opportunity for ZenaTech to expand its footprint. As industries increasingly turn to technology for operational optimization and cost reduction, ZenaTech’s diverse software offerings are essential in meeting these evolving demands.

ZenaTech (Nasdaq: ZENA) is positioned as an emerging player in the technology sector, offering a range of enterprise software solutions tailored to diverse industries. With its recent listing on the Nasdaq, the company aims to leverage its capabilities in AI, drone technology and SaaS solutions for future growth. As businesses increasingly look to technology for operational improvements, ZenaTech’s innovative products could serve as valuable tools in addressing current challenges across various sectors.

Disclaimers: RazorPitch Inc. “RazorPitch” is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by the company to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.

Media Contact
Company Name: RazorPitch
Contact Person: Mark McKelvie
Email: Send Email
City: NAPLES
State: Florida
Country: United States
Website: https://razorpitch.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: ZenaTech’s (Nasdaq: ZENA) Nasdaq Listing: A Launchpad for Growth and Innovation

Bumble Bee Blinds Enhances Home Elegance with Expanded Services in Alpharetta

Bumble Bee Blinds, a leading name in window treatments, proudly announces its expanded range of services in Alpharetta, GA, offering a comprehensive selection of solutions to enhance the beauty and functionality of homes. The company is now the go-to provider for Custom Blinds Alpharetta, Motorized Shades Alpharetta, Custom Shutters Alpharetta, Outdoor Shades Alpharetta, and Custom Draperies Alpharetta.

Alpharetta, GA – Bumble Bee Blinds is committed to quality and customer satisfaction and brings unparalleled expertise to the Alpharetta area. Their Custom Blinds Alpharetta service features diverse styles, colors, and materials to perfectly match any home décor. From sleek and modern to classic and traditional, their custom blinds are designed to provide both aesthetic appeal and practical benefits.

In addition, Bumble Bee Blinds now offers Motorized Shades Alpharetta for added convenience and modern functionality. These state-of-the-art shades can be controlled with a remote or smartphone, allowing homeowners to easily adjust lighting and privacy with just a touch.

The company’s Custom Shutters Alpharetta are crafted to add timeless charm and durability to any space. With options available to suit various tastes and architectural styles, these shutters enhance homes’ interior and exterior.

For those looking to extend their living space outdoors, Bumble Bee Blinds introduces Outdoor Shades Alpharetta. These shades protect from the elements while adding a stylish touch to patios and outdoor areas, ensuring comfort and privacy in any weather.

About Bumble Bee Blinds

Bumble Bee Blinds is a premier provider of custom window treatments in Alpharetta, GA. Focusing on quality, craftsmanship, and customer satisfaction, the company offers various solutions, including custom blinds, motorized shades, shutters, outdoor shades, and draperies. Its expert team is dedicated to delivering personalized service and superior products that enhance the beauty and functionality of every home.

Media Contact
Company Name: Bumble Bee Blinds (Alpharetta)
Contact Person: Brantley Smith
Email: Send Email
Phone: (770) 869-2837
Address:1740 Grassland Pkwy Unit 202
City: Alpharetta
State: GA
Country: United States
Website: https://www.bumblebeeblinds.com/north-atlanta-ga/

Jordan Wells Paving LLC Expands Premium Asphalt Services in Rockville

Jordan Wells Paving LLC, a leader in asphalt and paving services, announces the expansion of its professional services in the Rockville area. The company continues offering high-quality paving solutions and bringing years of expertise to residential and commercial projects.

Jordan Wells Paving LLC is a trusted Paving Contractor in Rockville known for delivering reliable and durable solutions. From driveway installations to parking lot paving, the company’s commitment to top-tier craftsmanship ensures that every project meets the highest quality standards.

In addition to residential services, the firm has expanded its commercial offerings, positioning itself as a leading Asphalt Contractor in Rockville. With a focus on efficiency, durability, and customer satisfaction, Jordan Wells Paving LLC specializes in asphalt resurfacing, sealcoating, and repairs, providing long-lasting solutions for property owners in the Rockville area.

The company’s expertise in asphalt paving in Rockville is backed by a team of skilled professionals who are well-versed in the latest techniques and equipment. From small-scale repairs to large paving projects, Jordan Wells Paving LLC guarantees high-performance results that enhance the functionality and appearance of paved surfaces.

With a dedication to delivering superior paving services, Jordan Wells Paving LLC remains a top choice for Rockville residents and businesses seeking professional asphalt and paving solutions.

About Jordan Wells Paving LLC

Jordan Wells Paving LLC is a premier paving company based in Rockville, Maryland. Specializing in asphalt paving and resurfacing, the company provides comprehensive services to both residential and commercial clients. With a focus on quality, reliability, and customer satisfaction, Jordan Wells Paving LLC remains a trusted name in the paving industry.

Media Contact
Company Name: Jordan Wells Paving LLC
Contact Person: Jordan Wells
Email: Send Email
Phone: (804) 315-3872
City: Rockville
State: Virginia
Country: United States
Website: https://jordanwellspavingllc.com/

Satellite IoT Market Recent Trends, Size, Share, Growth Outlook, Future Scope, Demand Outlook, Key Segments and Forecast to 2027

“Orbcomm (US), Iridium Communication (US), Globalstar (US), Astrocast (Switzerland), Inmarsat Global (UK), Airbus (Netherlands), Intelsat (US), Thales (France), Eutelsat (France), Northrop Grumman (US), Thuraya (Singapore), Vodafone (UK), Surrey Satellite Technology (UK), Head Aerospace (China).”

Satellite IoT Market by Service Type (Satellite IoT Backhaul, Direct-to-satellite), Frequency Band (L-Band, Ku and Ka-Band, S-band), Organization Size (Large Enterprises, Small and Medium Sized Enterprises), Vertical & Region – Global Forecast to 2027.

The global Satellite IoT market is projected to expand from USD 1.1 billion in 2022 to USD 2.9 billion by 2027, with a Compound Annual Growth Rate (CAGR) of 21.9% during the forecast period. This rapid growth is driven by the rising demand for reliable and cost-effective communication services, fueling the expansion of satellite IoT services.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=203680911

By frequency band, L-Band frequency is estimated to account for the largest market share in 2022

The L-band frequency operates within a range of 1–2 GHz. All GPS signals are in the L-band of the frequency spectrum (1–2 GHz). GPS units can receive accurate data in all weather conditions during the day or night, as L-band waves penetrate clouds, fog, rain, and storms. L-band is widely used in space-based platforms due to its capability for long-range applications. L-band is used extensively for fleet management and asset tracking. Israel Aerospace Industries offers ELM-2112FP Persistent Foliage Penetration satellite antenna, which uses the L-band in dense forest areas for surveillance.

L-band is viewed traditionally as the preferred option for applications involving small amounts of data transfer. Inmarsat uses an L-band satellite network as it offers the lowest latency and provides a resilient and flexible solution for IoT applications.

By organization size, SMEs are expected to register the fastest growth rate during the forecast period.

The adoption of satellite IoT services among small and medium-sized enterprises is expected to gain traction as it provides flexibility, scalability, and reduced operational costs. Satellite IoT services are used by various organizations, such as space agencies, private companies, individuals, institutes, the military, non-profit organizations, schools, and universities, for various applications. The major usage of satellite IoT is for research purposes in applications from earth observation to reconnaissance missions.

The satellite IoT industry offers SMEs a very lucrative opportunity because they don’t have to shoulder nearly as much capital expenditure as the established satellite network operators have.

Europe is likely to emerge as the fastest-growing market during the forecast period

Europe is anticipated to have highest CAGR for the forecasted period. The European region has a significant market share of the satellite IoT market due to the increased demand for remote sensing, Earth observation, and scientific exploration activities. The UK, Russia, Germany, Italy, Finland, and the Rest of Europe have been covered under this region. The ability of satellite IoT satellites to provide enhanced geospatial imagery has further boosted their demand in the region, as companies expect geospatial data to provide crucial information for supply chain management and business development. In 2021, the European Commission awarded a contract worth USD 1.7 billion to Thales Alenia Space and Airbus Defense and Space to develop an initial set of next-generation Galileo navigation satellites.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=203680911

Unique Features in the Satellite IoT Market

One of the standout features of Satellite IoT is its ability to provide global coverage, even in remote and rural areas where traditional terrestrial networks may not be available. This capability is crucial for industries such as agriculture, maritime, and logistics, allowing organizations to maintain connectivity and gather data from assets located in hard-to-reach locations.

Satellite IoT devices are designed to operate with low power consumption, enabling them to function efficiently in remote environments where power sources may be limited. This feature is essential for applications like wildlife tracking, environmental monitoring, and asset tracking, where devices may need to operate for extended periods without battery replacement.

Satellite IoT facilitates real-time data transmission, allowing businesses to receive timely updates on their assets and operations. This feature is particularly valuable in applications such as fleet management, emergency response, and remote monitoring, where timely information can lead to faster decision-making and improved operational efficiency.

The Satellite IoT market offers scalable solutions that can grow with the needs of an organization. As the number of connected devices increases, satellite networks can support additional devices without the limitations often associated with terrestrial networks. This scalability is crucial for industries adopting IoT technologies on a larger scale.

Security is a critical concern in IoT, and Satellite IoT systems incorporate advanced security features to protect data transmitted over satellite networks. Encryption, authentication protocols, and secure communication channels help safeguard sensitive information from potential cyber threats, making Satellite IoT suitable for applications requiring high security, such as defense and critical infrastructure monitoring.

Major Highlights of the Satellite IoT Market

A major highlight of the Satellite IoT market is its ability to provide global connectivity, making it possible to monitor and manage assets in the most remote locations. This feature is particularly beneficial for industries such as agriculture, logistics, and maritime, where traditional terrestrial networks may be unavailable or unreliable.

The growing adoption of IoT technologies across various sectors is a key driver for the Satellite IoT market. As businesses seek to leverage data for operational efficiencies, the need for reliable and scalable communication solutions is becoming paramount, making Satellite IoT an attractive option for many organizations.

Satellite IoT enables continuous and real-time data collection from remote devices, allowing organizations to monitor assets effectively. This capability is particularly valuable for applications such as environmental monitoring, agriculture, and disaster management, where timely data can lead to better decision-making and improved outcomes.

The market is benefiting from advancements in satellite technology, including the deployment of small satellites and low Earth orbit (LEO) constellations. These innovations enhance connectivity, reduce latency, and improve overall service quality, making Satellite IoT solutions more efficient and effective.

The emergence of new technologies is leading to more cost-effective Satellite IoT solutions. As prices for satellite connectivity continue to decline, businesses can implement IoT solutions without incurring prohibitive costs, making it an increasingly attractive option for various applications.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=203680911

Top Companies in the Satellite IoT Market

The major vendors covered in the satellite IoT market include Orbcomm (US), Iridium Communication (US), Globalstar (US), Astrocast (Switzerland), Inmarsat Global (UK), Airbus (Netherlands), Intelsat (US), Thales (France), Eutelsat (France), Northrop Grumman (US), Thuraya (Singapore), Vodafone (UK), Surrey Satellite Technology (UK), Head Aerospace (China), I.M.T. SRL (Italy), Fleetspace Technologies (Australia), Swarm Technologies (US), Alenspace (Spain), OQ Technology (Luxembourg), Fossa Systems (Spain), Kepler Communications (Canada), Sateliot (Spain), Myriota (Australia), Kineis (France), and Nanoavionics (Lithuania).

Orbcomm (US) a global leader and innovator in the industrial Internet of Things, provides solutions that connect businesses to their assets to deliver increased visibility and operational efficiency. It was acquired by GI Partners in September 2021. It offers a broad set of asset monitoring and control solutions, including seamless satellite and cellular connectivity, unique hardware, and powerful applications, all backed by end-to-end customer support, from installation to deployment to customer care. ORBCOMM’s satellite and dual-mode satellite-cellular terminals deliver complete visibility and control of industrial assets operating in remote areas, with global satellite connectivity over Inmarsat’s IsatData Pro network.

Astrocast (Switzerland) is a company that deals in the satellite IoT industry. It provides leading integrated solutions that enable cost-effective SatIoT communications. The company offers satellite services from satellite infrastructure, fully designed, assembled, and in-house operated. Astrocast offers a bidirectional and highly secure connection to any IoT device on Earth. The company delivers its services to industries, such as maritime, environmental, mining, oil and gas, connected vehicles, agriculture and livestock, and asset monitoring. Astrocast is developing global nanosatellite constellations and low-power modules to ubiquitously connect, efficiently and at ultra-low-cost, millions of IoT devices in remote, rural and maritime areas.

Inmarsat Global (UK) is a leading provider of satellite IoT solutions. Leveraging its extensive satellite network coverage, the company offers reliable and scalable connectivity for IoT devices in remote and challenging environments worldwide. Inmarsat’s IoT offerings cater to various industries, including maritime, aviation, agriculture, and energy, enabling businesses to track assets, monitor operations, and access critical data regardless of location. Their solutions emphasize global coverage, low-latency communications, and integration with IoT platforms, empowering enterprises to unlock new opportunities and optimize their operations through satellite-based IoT connectivity.

Airbus (Netherlands) is a key player in the satellite IoT sector. The company provides end-to-end satellite IoT solutions, leveraging its expertise in aerospace and telecommunications. Airbus offers satellite connectivity services tailored for IoT applications, enabling remote monitoring, tracking, and data collection across various industries such as transportation, agriculture, and environmental monitoring. Their solutions focus on global coverage, low-power consumption, and seamless integration with IoT platforms, empowering businesses to harness the benefits of satellite-based IoT connectivity for improved efficiency and decision-making.

Thales (France) is a leading provider of satellite IoT solutions. Leveraging its expertise in aerospace, defense, and cybersecurity, Thales offers comprehensive satellite connectivity services tailored for IoT applications. Their solutions encompass satellite communication terminals, network infrastructure, and management platforms, enabling reliable and secure data transmission for remote monitoring, tracking, and asset management across various industries. Thales emphasizes global coverage, robust security features, and integration with IoT platforms, empowering businesses to leverage satellite-based IoT connectivity for enhanced operational efficiency and decision-making capabilities

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103
City: Delray Beach
State: FL 33445
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/satellite-iot-market-203680911.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Satellite IoT Market Recent Trends, Size, Share, Growth Outlook, Future Scope, Demand Outlook, Key Segments and Forecast to 2027

API Management Market Growing Trends, Business Growth, Size, Future Scope, Segmentation, Dynamics and Forecast to 2029

“Google (US), IBM (US), AWS (US), Microsoft (US), MuleSoft (US), Axway (France), Software AG (Germany), WSO2 (US), Broadcom (US), and TIBCO Software (US).”

API Management Market by Platform (API Gateways, API Lifecycle Management, API Security, API Analytics & Monitoring, API Developer Portal), Service (Integration & Implementation, Support & Maintenance, Training & Education) – Global Forecast to 2029.

The API management market is projected to grow from USD 7.67 billion in 2024 to USD 16.93 billion by 2029, at a Compound Annual Growth Rate (CAGR) of 17.1% during the forecast period. API management platforms provide a customized approach to API design, implementation, and oversight, setting them apart from traditional methods through centralized control and monitoring. This software-based framework enables seamless API lifecycle management, enhancing both scalability and security.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=178266736

The services segment is expected to capture the highest CAGR during the forecast period by offering.

API management services are crucial in managing the API throughout its lifecycle and guaranteeing that the APIs developed are secure, elastic, and high-performing. Such services are usually comprised of API design and development tools through which organizations can design and build adequate and reliable APIs for use within their business operations. When APIs are deployed, management services offer API gateways that facilitate traffic management distribution of loads and security shields that shield the APIs from potential threats and other risks that may hinder their proper functioning. Security elements are an essential component of the API management services that provide various advanced features such as authorization and authentication mechanisms to protect multiple APIs and their data from unauthorized access, along with encryption to meet regulatory compliances to some extent. Moreover, these services come with features that offer an API’s performance, usage, and possible real-time problems, enabling organizations to manage API strategies efficiently.

API management services also facilitate developer interaction by having portals containing documentation, testing beds, and support materials for use. This makes it easier to implement API into software and increases the rate of development, thus improving the developer’s experience. Also, these services provide additional features for API monetization and analytics, which help organizations measure usage and apply charging models that will bring revenues.

Based on the platform, the lifecycle management segment is expected to hold the second largest market share during the forecast period.

API lifecycle management is the process of designing, building, deploying, and managing APIs during their entire lifetime. This management guarantees that APIs are properly created, tested, launched, and monitored to fulfill both business and technical requirements. The lifecycle begins with API designing and planning, which defines the API’s goals, functionality, and standards. This step entails developing a blueprint that defines the API’s endpoints, data structures, and interactions.

Following design, the development step involves developing the API, verifying correct integration with backend systems, and meeting performance targets. This is followed by thorough testing to discover and resolve any bugs before the API is released into production. Once the API is live, it moves on to the deployment step.

North America is projected to hold the largest market share during the forecast period.

North America’s API management market is expected to grow significantly in the near future as the region demonstrates constant digitalization prevalence of cloud, microservice, and mobile applications. APIs are used in almost all business sectors, such as banking, healthcare, retail, and telecommunication, to support business functions, improve the customer experience, and integrate with third-party service providers. Large vendors such as Google, IBM, Microsoft, and MuleSoft drive this market through integrated API management platforms, including API design, development, security, and monitoring. These companies rely on horizontal and vertical growth to bring up their portfolios and meet customers’ needs. The market is also experiencing growth due to the increasing need for more secure and expandable API platforms, which is resulting from increasing security concerns and compliance issues. Moreover, the demands for digital banking, the emergence of fintech solutions, and the influence of IoT devices positively impact the adoption of API management platforms in the region. High maturity and adoption of IT solutions in the North American market, along with several prominent investments in technology infrastructure, makes it an essential region in the API management market, especially with considerable US dominance in investments and innovation.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=178266736

Unique Features in the API Management Market

API management platforms provide centralized control over the entire API lifecycle, from design and implementation to monitoring and deprecation. This centralized governance allows businesses to manage APIs more efficiently by setting global policies, ensuring compliance, and maintaining security across all their APIs, which is difficult to achieve with decentralized approaches.

One of the key features of API management platforms is their ability to handle the entire lifecycle of an API, from creation and testing to deployment, monitoring, and retirement. These tools enable organizations to manage the development and evolution of APIs, ensuring they remain secure, performant, and up-to-date throughout their lifecycle.

API management platforms offer robust security features, such as OAuth, API key management, and token-based authentication, to protect APIs from unauthorized access and misuse. They also support advanced security measures like rate limiting, throttling, and IP whitelisting to safeguard against cyberattacks and ensure that APIs are only accessed by authorized users or applications.

These platforms are built to ensure that APIs can scale seamlessly as the number of users or requests grows. They offer load balancing features that distribute traffic across multiple servers or instances, ensuring that APIs remain responsive and available even during peak demand. This scalability makes API management solutions ideal for businesses with growing user bases or fluctuating traffic patterns.

API management solutions provide detailed analytics and monitoring capabilities, giving businesses insights into API performance, usage patterns, and potential issues. Real-time data and reporting help organizations track key metrics like response times, error rates, and throughput, allowing them to optimize APIs, detect bottlenecks, and enhance the user experience.

Major Highlights of the API Management Market

With the growing usage of APIs, the need for robust security measures has become paramount. API management platforms provide comprehensive security features like token-based authentication, encryption, and role-based access control, helping organizations protect their APIs from threats such as data breaches, unauthorized access, and cyberattacks.

API management solutions enable organizations to maintain centralized control over their APIs, facilitating efficient design, deployment, and monitoring processes. This centralized approach simplifies the management of multiple APIs across different environments, ensuring consistency in performance, security, and policy enforcement.

A key highlight of API management platforms is their ability to manage the entire API lifecycle. From creation and testing to deployment, monitoring, and decommissioning, API management tools streamline every stage, ensuring that APIs remain secure, performant, and optimized as business needs evolve.

API management platforms are built for scalability, supporting high-traffic environments and ensuring that APIs can handle increased demand without compromising performance. Features such as load balancing and traffic routing allow APIs to scale seamlessly, meeting the needs of organizations that experience rapid user growth or seasonal spikes in usage.

Many API management platforms feature developer portals that simplify the process of accessing and integrating APIs. These portals provide comprehensive documentation, testing environments, and collaboration tools, making it easier for developers to understand, test, and work with APIs. This focus on enhancing the developer experience accelerates API adoption and integration.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=178266736

Top Companies in the API Management Market

Major vendors in this market are in North America and Europe. Google (US), IBM (US), AWS (US), Microsoft (US), MuleSoft (US), Axway (France), Software AG (Germany), WSO2 (US), Broadcom (US), and TIBCO Software (US) are among the leading players operating in the API management market. These players have adopted many growth strategies to strengthen their position in the market. These include product launches, contracts, partnerships, collaborations, mergers, acquisitions, and new product development activities to expand market presence.

Google

Google is a US-based multinational technology company specializing in internet-based products and services, including online advertising technologies, cloud computing, software, and hardware. Google is considered one of the big five companies in the American information technology industry.

Google’s cloud technology is an effective solution to business problems, with cloud solutions available for various industries, such as retail, consumer packaged goods, financial services, healthcare and life sciences, media and entertainment, gaming, telecom, and manufacturing. Google Cloud offers a wide range of services, including data cloud, artificial intelligence (AI), APIs and apps, security, digital transformation, and databases. Its primary income streams are app sales, in-app payments, advertising, and digital content items, with additional investments in analytics, infrastructure, data management, and AI. The company also offers Google Analytics, enabling customers to customize monitoring of their social media or websites from mobile and web apps without charge. Google also has a stronghold in the API management market; it offers a platform for organizations to design, protect, and manage APIs.

Microsoft

Microsoft is an American multinational technology corporation famous for its innovation in operating systems, specifically MS-DOS and Windows. Microsoft, the world’s biggest supplier of computer software, has a diversified portfolio in personal computing, entertainment, corporate cloud computing, and artificial intelligence. Primarily, Microsoft deals with the Windows OS, Microsoft Office 365 suite of productivity applications, and its Edge web browser. Alongside the software, Microsoft has made considerable investments in cloud computing through Azure, a comprehensive portfolio platform that provides computing, analytics, storage, and networking services. Azure develops and scales applications within the public cloud to provide services across various industries and needs. Microsoft has offices in over 60 countries and is headquartered in Redmond, Washington.

Microsoft is one of the major players in the API management market with its robust Azure platform, offering services like Azure API management for designing and publishing APIs, setting access controls, monitoring usage, and ensuring API security. Azure API Management enables hybrid and multi-cloud architectures, links with various Azure services, and includes advanced functions such as API analytics, developer portals, and versioning.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: API Management Market Growing Trends, Business Growth, Size, Future Scope, Segmentation, Dynamics and Forecast to 2029